Phase I / II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL / SLL and NHL
Trial Status: Active
Phase I / II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL / SLL and NHL
Inclusion Criteria
- Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia, or Non-Hodgkin's Lymphoma
- Refractory to or relapsed after at least 1 prior treatment regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Known histological transformation from CLL to an aggressive lymphoma (Richter's)
Illinois
Chicago
Northwestern University
Status: ACTIVE
Ohio
Cleveland
Case Comprehensive Cancer Center
Status: ACTIVE
Trial Phase Phase I/II
Trial Type Treatment
Lead Organization
TG Therapeutics Inc
- Primary ID U2-VEN-109
- Secondary IDs NCI-2018-01293
- Clinicaltrials.gov ID NCT03379051